In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

ICHealth: Large-scale digital health data on evidence-based cardiovascular medications, hospitalizations and epidemiological characteristics of heart failure patients in Brazil

Session e-Cardiology / Digital Health ePosters

Speaker Doctor Karla Santo

Event : ESC Congress 2020

  • Topic : e-cardiology/digital health. public health. health economics. research methodology
  • Sub-topic : Big Data and Digital Twin
  • Session type : e-posters

Authors : K Santo (Sao Paulo,BR), P Marton (São Paulo,BR), M Lapa (Sao Paulo,BR), P Pereira (São Paulo,BR), E Amaro (Sao Paulo,BR), O Berwanger (Sao Paulo,BR)

K Santo1 , P Marton2 , M Lapa1 , P Pereira2 , E Amaro1 , O Berwanger1 , 1Hospital Israelita Albert Einstein - Sao Paulo - Brazil , 2ePHealth - São Paulo - Brazil ,

Digital Health: Big Data Analysis

INTRODUCTION: Heart failure (HF) is one of the main causes of morbimortality in Brazil. However, little is known about the characteristics of the Brazilian HF population assisted at the community level, including the use of HF medications and frequency of hospitalizations. ePHealth is an app-based large-scale digital data collection platform that currently has health data on more than 1.5 million people.

PURPOSE: To assess the use of evidence-based HF medications, hospitalizations and epidemiological characteristics of HF patients in Brazil.

METHODS: This is an observational retrospective study of the digital health data collected using the ePHealth platform on individuals, who self-reported a diagnosis of HF. Data collected included sociodemographics, clinical data, risk factors, comorbidities, medications and hospitalizations.

RESULTS: Data collected at more than 40,000 home visits on 5907 individuals with HF were analysed. Majority of them were female, aged 55 to 75 years and brown (Figure). About 36% were married, 20% were illiterate, 65% were retired and 66% earned = 2 minimum wages. Mean BMI was 26.7 kg/m2 (SD 5.9), risk factors and comorbidities were frequent (Figure). The use of HF medications was very low (Table). There were 575 hospitalizations (9.7%), due to the main following reasons: probable or definite heart failure decompensation (89, 15.5%), heart attack (60, 10.4%), cardiovascular procedures (54, 9.4%) and stroke (42, 7.3%).

CONCLUSION: This data suggests that community-level use of evidence-based cardiovascular medications in a population of individuals with HF in Brazil is very low and that hospitalizations are frequent. This study also provides a better understanding of the characteristics of a population of HF individuals, using large-scale real-world data collected on a community-level via an entirely digital platform. ePHealth is a disruptive platform able to provide data on the burden of HF and other cardiovascular diseases, informing decisions on implementation of prevention and management programmes.

Use of cardiovascular medications by class N (%)
ACE inhibitors/ ARBs 1368/5907 (23.2%)
Beta-blockers 968/5907 (16.4%)
Loop diuretics 368/5907 (6.2%)
Aldosterone antagonists 332/5907 (5.6%)
Digitalis 146/5907 (2.5%)
Ivabradine 34/5907 (0.6%)
N, number ACE, angiotensin converting enzyme ARB, angiotension receptor blocker HF, heart failure

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are